Compare DexCom, Inc. (DXCM) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs InMode Ltd — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while InMode Ltd trades at $15.25 (market cap $872.08M). The key difference: DexCom, Inc. is far larger — about 38.7× InMode Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | INMD | |
|---|---|---|
Market Cap | $33.79B | $872.08M |
Sector | Health | Technology |
52-Week High | $89.53 | $16.62 |
52-Week Low | $54.84 | $12.76 |
Enterprise Value | $33.24B | $375.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
INMD trades at $15.23, up 0.26% today, with a neutral technical outlook and mixed earnings history including a Q1 2026 miss. The company reported Q2 2026 revenue of $95.6 million, consistent year-over-year, and maintains a strong gross profit margin of 76.52%. Recent news highlights an unsolicited acquisition offer from Steel Partners at $16.75 per share and shareholder activism urging rejection, creating uncertainty around corporate governance.
The stock presents a value opportunity with low P/E and EV/EBITDA ratios, but risks include earnings volatility, potential acquisition fallout, and ongoing securities fraud investigations. Analyst consensus is divided between Buy and Hold ratings, reflecting cautious optimism amid near-term headwinds. Long-term growth depends on execution of international expansion and innovation in medical technologies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
